Navigation Links
A second pathway for antidepressants
Date:2/7/2011

itous of these transmembrane proteins, gating the passage of potassium ions through neural membranes, which sets the excitability of the neuron. Earlier studies had shown that when the TREK1 gene is "knocked out" of mice, the mice display a depression-resistant phenotype that mimics the behavior of mice treated with fluoxetine and that the antidepressant inhibits the activity of the TREK1 channel. While these results pointed to a possible role for the TREK1 ion channel in the beneficial response to fluoxetine, the mechanism behind this activity was unclear.

"Studying what the different protein parts of an ion channel do is a huge challenge," Isacoff says. "Over the years, my group has developed techniques by which the domains of channel proteins can be labeled with site-specific fluorescent dyes. Structural rearrangements of the labeled sites in the channel can then be detected through changes in the fluorescence."

Isacoff and his group separated the C-terminal domain from the rest of the protein and tagged it with a green fluorescent protein (GFP) - a fluorescent protein from jellyfish commonly used to paint cells green for biological studies. Whereas the pore of the TREK1 ion channel is embedded in the plasma membrane of a neuron, the C-terminal is a short tail that protrudes out into the surrounding cytoplasm.

Using voltage clamps to measure electrical currents through the channel and fluorescence to monitor the disposition of the C-terminal domain, Isacoff and his group found that when the C-terminal tail is fully bound to the plasma membrane, the TREK1 potassium channel opens more; when the tail is unbound from the plasma membrane, the ion channel tends to close.

"We found that fluoxetine causes the isolated C-terminal domain to unbind from the membrane and also causes an inhibition of current from the full TREK1 channel," Isacoff says.

The next step will be to see how the C-terminal tail is affected by the pre
'/>"/>

Contact: Lynn Yarris
lcyarris@lbl.gov
510-486-5375
DOE/Lawrence Berkeley National Laboratory
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Out of mind in a matter of seconds
2. MegaMatcher Accelerator 3.0 for Rapid Biometric Identification Matches Up to 200 Million Irises or 100 Million Fingerprints Per Second
3. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
4. Probing the mysterious second-wave of damage in head injury patients
5. Second-generation device more effective in capturing circulating tumor cells
6. Autism Speaks awards second class of Dennis Weatherstone pre-doctoral fellowships
7. Aware, Inc. Reports Second Quarter 2010 Financial Results
8. BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule
9. Teleconference Alert: LyondellBasell Reviews Second Quarter 2010 Financial Results
10. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
11. De La Rue Provides Second-Generation ePassport for Malta
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A second pathway for antidepressants
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... , SAN FRANCISCO, CAFebruary 9, 2014Sometimes biology is cruel. ... code is the difference between health and a deadly ... studied disorders caused by these tiny changes, replicating them ... But now, scientists at the Gladstone Institutes have found ...
... regions associated with type 2 diabetes have been identified ... basis of the disease. DNA data was brought ... controls from four different ethnic groups. The research was ... countries on four continents, co-led by investigators from Oxford ...
... reaction usually is "Eww," but when they see a ... Why some animals use noxious scents while others ... is the question that biologists Tim Caro of the ... State University, Long Beach and sought to answer ...
Cached Biology News:Genome editing goes hi-fi 2Genome editing goes hi-fi 3Seven new genetic regions linked to type 2 diabetes 2Social or stinky? New study reveals how animal defenses evolve 2
(Date:4/24/2015)... April 24, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... biosimilar therapeutics including high value and difficult to manufacture ... offering of 6,000,000 shares of its common stock at ... Of the shares being offered, 2,610,000 are being offered ... offered by existing stockholders. Pfenex will not receive any ...
(Date:4/24/2015)... 24, 2015  Navitas Life Sciences is delighted to announce ... Clinical and Regulatory Services. Shalabh is a proven leader in ... CEO of Kinapse, as well as a Strategy consultant at ... - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... "I am delighted to welcome Shalabh into this critical role ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 Athena San ... development of executive women in San Diego’s technology and ... 17th Annual Pinnacle Awards at their Gala on April ... Hotel. Register now at http://athenasd.org/events/ , The ... the Athena San Diego vision of fostering networking, risk ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
... 28, 2011 Nature,s Bioceuticals, a wholly owned subsidiary ... billion market chronic obstructive pulmonary disease market (COPD) with ... This all natural, non-synthetic, medicine was developed for the ... which are Emphysema and Chronic Bronchitis. We believe that ...
... at the Georgia Institute of Technology have developed a ... a key ingredient found in many explosives. ... on paper or paper-like material using standard inkjet technology, ... to the presence of explosives, such as improvised explosive ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... to Halozyme,s clinical stage drug, pegylated rHuPH20 (PEGPH20). The ... on "Molecular Markers in Cancer", taking place October 27-29 ...
Cached Biology Technology:Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 2Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 3Low-cost paper-based wireless sensor could help detect explosive devices 2Low-cost paper-based wireless sensor could help detect explosive devices 3Low-cost paper-based wireless sensor could help detect explosive devices 4Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 2Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 3
normal rat IgM AF647...
Request Info...
Request Info...
... , 2 x 50 ml 10X TBST Wash Buffer ... ml BL21 glycerol stock , 0.2 ml BLT5403 glycerol ... 1010 pfu T7Select Positive Control Lysate , 1010 pfu ... Conjugate , 2 ml T7Select S-protein , 50 ...
Biology Products: